Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Fifth Third Bancorp

Fifth Third Bancorp decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.0% in the 1st quarter, HoldingsChannel.com reports. The firm owned 7,691 shares of the biopharmaceutical company’s stock after selling 952 shares during the quarter. Fifth Third Bancorp’s holdings in Regeneron Pharmaceuticals were worth $4,878,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of REGN. Pinney & Scofield Inc. acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth approximately $25,000. OFI Invest Asset Management purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $28,000. Rakuten Securities Inc. grew its stake in Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 15 shares during the period. Tompkins Financial Corp purchased a new stake in Regeneron Pharmaceuticals during the first quarter worth approximately $32,000. Finally, Curat Global LLC purchased a new stake in Regeneron Pharmaceuticals during the first quarter worth approximately $32,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 1.4%

NASDAQ REGN opened at $529.24 on Friday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The company has a market capitalization of $57.14 billion, a price-to-earnings ratio of 13.83, a price-to-earnings-growth ratio of 2.34 and a beta of 0.31. The company’s fifty day moving average price is $563.19 and its two-hundred day moving average price is $649.98.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. During the same quarter last year, the company earned $9.55 earnings per share. The company’s revenue was down 3.7% compared to the same quarter last year. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were paid a dividend of $0.88 per share. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.67%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.96%.

Analyst Ratings Changes

Several equities research analysts have issued reports on REGN shares. BMO Capital Markets decreased their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an “outperform” rating for the company in a research note on Monday, June 2nd. Bank of America decreased their price objective on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating for the company in a research note on Thursday, April 17th. UBS Group decreased their price objective on shares of Regeneron Pharmaceuticals from $633.00 to $560.00 and set a “neutral” rating for the company in a research note on Thursday, June 5th. JPMorgan Chase & Co. decreased their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an “overweight” rating for the company in a research note on Monday, June 9th. Finally, Royal Bank of Canada downgraded shares of Regeneron Pharmaceuticals from a “moderate buy” rating to a “hold” rating and set a $662.00 price objective for the company. in a research note on Friday, May 30th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $836.48.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.